Ethyl butyrate (C6H12O2) also known as ethyl butanoate, or butyric ether is an ester. Ethyl butyrate is used as an extract, as a flavoring or perfume, and as a solvent. It is a colorless liquid with a banana, orange or pineapple odor, and it is flammable. Exposure to ethyl butyrate can irritate the skin, eye, nose and throat. Applications include: artificial flavoring resembling orange juice or pineapple in alcoholic beverages, as a solvent in perfumes, and as a plasticizer for cellulose.

Hydrocortisone caproate is a synthetic steroid hormone and 21-O-hexanoyl derivative of hydrocortisone. Hydroxyprogesterone caproate was previously marketed under the trade name Delalutin by Squibb, which was approved by the U.S. Food and Drug Administration (FDA) in 1956 and withdrawn from marketing in 1999. Hydrocortisone caproate acts by binding to progesterone receptors in the uterus, ovaries, breasts and in the central nervous system. These receptors exist in 2 isoforms, PR-A and PR-B. Hydrocortisone caproate binding to these receptors ultimately leads to regulation of gene transcription. This results in an anti-inflammatory effect which blunts the proinflammatory state that occurs with the initiation of labor and maintains uterine quiescence by stabilizing progesterone acting on the myometrium. Following intramuscular injection, approximately 50% of hydroxyprogesterone caproate metabolites are eliminated in the feces, while approximately 30% of metabolites are eliminated in the urine. Injection site pain is the most common adverse effect associated with hydroxyprogesterone caproate. Other commonly reported adverse effects include injection site swelling, urticaria, pruritus, injection site pruritus, nausea, injection site nodule, and diarrhea.

Resocortol butyrate is a corticosteroid which has a high intrinsic glucocorticoid activity. Its mineralocorticoid and progestational activity is very low. Resocortol butyrate has local and systemic glucocorticoid effects. The expression of these effects depends on the mode of application and the dosage applied. After topical application on the skin, a local anti-inflammatory effect is seen, which is accompanied by a moderate and reversible adrenal suppression at higher doses. After oral administration in dogs few systemic effects were observed. Resocortol butyrate was marketed under the brand name Pruban as the topical cream for the treatment of acute localised moist dermatitis in dogs. It was discontinued.